

Introduction

In my appearance today on behalf of Pennwalt and its Pharmaceutical Division, I will review those major considerations which we believe to be responsive to this Committee's invitation.

In order that you may readily comprehend our views, I should like to summarize them at the outset and then deal with them more fully by major category.

As part of Pennwalt Corporation, a 126-year old firm founded and still headquartered in Philadelphia, Pennsylvania, with annual sales of approximately \$750 million, we share its pride in our collective integrity. (I should note that our division represents less than ten percent of the Company's total sales, and that our anti-obesity products represent less than three percent of total sales, with less than one percent in anorectic amphetamine products.)

Anti-obesity prescription medicine is the only federally recognized effective medicinal aid available in a course of medically supervised anti-obesity treatment available to the 30 to 40 million Americans who are obese, namely, those who are at least 20 percent overweight.

Obesity is a recognized illness, in medical terms, as well as an emotional burden. It also complicates other quite serious medical problems.

Our Pharmaceutical Division clearly recognizes that its anorectic products should not be used unless prescribed by a physician. We firmly believe that our marketing program fully reflects this recognition and contains no suggestion that we seek to sell the patient any use of our anorectic products.